Avacta Therapeutics (AIM: AVCT) has announced plans to present its next-generation dual-payload cancer drug candidate AVA6207 at the 2026 EORTC-NCI-AACR Symposium in Barcelona, highlighting a new approach designed to overcome
Avacta reports 11.4-month progression-free survival with AVA6000 in salivary gland cancer trial
Avacta Therapeutics (AIM: AVCT) has reported encouraging clinical results from its ongoing Phase 1a/1b trial of faridoxorubicin (AVA6000), with median progression-free survival reaching 11.4 months in a selected group of
Avacta reports promising AVA6103 cancer trial progress with tumour responses in Enhertu-resistant models
Avacta Therapeutics (AIM: AVCT) has reported encouraging preclinical results for its experimental cancer treatment AVA6103, demonstrating tumour responses in models resistant to Enhertu, as the company advances its Phase 1
Avacta to present cancer trial survival data and AVA6103 study design at ESMO 2026
Avacta Therapeutics (AIM: AVCT) will present updated clinical data from its Faridoxorubicin (AVA6000) cancer programme and details of its AVA6103 trial at the European Society for Medical Oncology (ESMO) Congress
Avacta Therapeutics Raises £12.5m as Trading Resumes After Capital Access Window
Avacta Therapeutics (AIM: AVCT) has conditionally raised £12.5 million gross through a placing and director subscription priced at 68p per share.
Avacta Therapeutics Seeks £12.5m to Extend Cash Runway Into Q2 2027
Avacta Therapeutics (AIM: AVCT) has launched an accelerated bookbuild and subscription seeking minimum gross proceeds of approximately £12.5 million.
Avacta Opens Capital Access Window Ahead of Equity Fundraise
Avacta (AIM: AVCT) currently expects its existing cash resources to last into early Q1 2027 and is continuing discussions with potential partners for its next-generation assets.
Avacta Group Further Demonstration of Potential of AVA6103
Avacta Therapeutics (AIM: AVCT) has presented the design of its Phase 1 FOCUS-01 trial and updated preclinical data supporting AVA6103 in pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic
Avacta Reports Clinical Proof of Mechanism for AVA6103 in Phase 1 Trial
Avacta Therapeutics (AIM: AVCT) has reported clinical proof of mechanism for AVA6103, its next-generation pre|CISION® peptide-drug conjugate, from the ongoing Phase 1 FOCUS-01 trial.
Avacta Appoints Mats Blom to Board as Audit Committee Chair
Avacta Therapeutics (AIM: AVCT) has appointed experienced biotechnology finance executive Mats Blom to its Board of Directors, where he will also serve as Chair of the Audit Committee.
Avacta pays £2.61m bond instalment as debt falls to £12m
Avacta Therapeutics (AIM: AVCT) has settled an accelerated deferred convertible bond repayment of £2.613 million in cash, reducing the remaining principal under the facility to £12 million.
Avacta Awards CEO 13.4m Share Options at 69p as Clinical Pipeline Advances
Avacta (AIM: AVCT) has granted a substantial package of share options to its management team, including 13.4 million options to chief executive Christina Coughlin, as part of an incentive and